Search the Newsreel

IDEXX Laboratories Q2 2026 Earnings Call Transcript

IDEXX Laboratories reported strong Q2 2026 financial results, with a 10% revenue increase and a raised full-year outlook. The company highlighted robust growth in CAG Diagnostics, Water, and LPD businesses, driven by innovation, increased diagnostic utilization, and expanding customer

IDEXX Laboratories Announces Second Quarter Results

IDEXX Laboratories reported strong second quarter 2026 results, with revenue growth of 10% and EPS increasing by 18%. The company's Companion Animal Group Diagnostics recurring revenue grew by 11%, driven by innovation and increased diagnostic utilization. IDEXX also narrowed its 2026 revenue guidance and …

Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates

Idexx Laboratories (IDXX) reported strong Q2 2026 earnings, beating Zacks Consensus Estimates for both earnings per share ($4.27 vs. $3.95) and revenues ($1.22 billion vs. $1.20 billion). The company has consistently surpassed analyst expectations over the past four quarters. Despite the positive results, Idexx …

IDEXX Labs earnings beat by $0.31, revenue topped estimates

IDEXX Labs (NASDAQ: IDXX) reported strong Q2 results, with EPS of $4.27 surpassing analyst estimates by $0.31 and revenue reaching $1.22 billion, exceeding the consensus. The company also provided optimistic FY 2026 guidance, projecting EPS between $14.69 and $14.94 and revenue of $4.70 billion …

Earnings Flash (IDXX) IDEXX Laboratories Posts Q2 Adjusted EPS $4.07, vs. FactSet Est of $3.94

IDEXX Laboratories (IDXX) announced its Q2 adjusted earnings per share (EPS) of $4.07, surpassing the FactSet estimate of $3.94. The company also reported increased Q2 comparable earnings and revenue, and provided an updated 2026 outlook. IDEXX Laboratories is a global leader in diagnostic instruments …

Earnings Flash (IDXX) IDEXX Laboratories, Inc. Reports Q2 Revenue $1.22B, vs. FactSet Est of $1.20B

IDEXX Laboratories, Inc. (IDXX) reported strong second-quarter results, with revenue reaching $1.22 billion, surpassing FactSet's estimate of $1.20 billion. The company also announced adjusted EPS of $4.07, exceeding the FactSet estimate of $3.94. This positive earnings flash highlights IDEXX's continued growth in the medical …

IDEXX Labs stock rises nearly 4% on earnings beat and raised guidance

IDEXX Laboratories Inc. reported strong second-quarter results, exceeding analyst expectations for both adjusted EPS and revenue. The company also raised its full-year 2026 EPS guidance, leading to a nearly 4% rise in its stock during pre-market trading. Key drivers included the "Technology for Life" …

IDEXX Laboratories, Inc. (NASDAQ: IDXX) lifts 2026 outlook after strong Q2

Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say

Update: IDEXX Laboratories' Q2 Earnings, Revenue Increase; 2026 Outlook Updated

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook

Why Is IDEXX Laboratories Stock Gaining Tuesday?

IDEXX Laboratories (NASDAQ: IDXX) stock rose on Tuesday after the company reported strong second-quarter results that exceeded Wall Street estimates and subsequently raised its full-year earnings outlook for 2026. The growth was primarily driven by its Companion Animal Diagnostics segment, despite a slight decline …

IDEXX Laboratories Inc Stock Price Live, Charts & News

This article provides live stock information for IDEXX Laboratories Inc (IDXX), including its current share price, historical performance, and key financial metrics like market capitalization, PE ratio, and dividend yield. It also presents the company's balance sheet, income statement, and cash flow data up …

IDEXX Laboratories (IDXX) director granted 49 deferred stock units

IDEXX Laboratories director Joseph L. Hooley acquired 49 deferred stock units on July 30, 2026, under the company's Director Deferred Compensation Plan. These units, valued at $27,280.22 based on a closing share price of $558.80, vest immediately and will be paid in stock after …

IDEXX earnings on deck: Can innovation sustain growth momentum?

IDEXX Laboratories Inc. is set to report its second-quarter earnings, with investors keen to see if the company can maintain its growth trajectory. Analysts anticipate EPS of $3.96 and revenue of $1.20 billion, driven by strong performance in Companion Animal Group diagnostics and adoption …

ETFs Investing in IDEXX Laboratories, Inc. Stocks

This article lists various ETFs that include IDEXX Laboratories, Inc. (IDXX) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of IDXX, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV …

Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX

The article provides the Enterprise Value to EBITDA forward for IDEXX Laboratories, Inc. (NASDAQ: IDXX). It indicates that the market was closed at the time of data retrieval and that there were no trades. The content primarily focuses on financial data availability for the …

IDEXX Laboratories Inc. stock outperforms competitors despite losses on the day

IDEXX Laboratories Inc. (IDXX) shares declined by 1.93% on Thursday, closing at $558.80, despite a generally positive trading session for the broader market. This drop ended a four-day winning streak for the company's stock.

Is IDEXX Laboratories (IDXX) Fairly Valued After Its 2025 Corporate Responsibility Report?

IDEXX Laboratories (IDXX) Could Be 20% Below Fair Value On Its Diagnostics Growth Story

IDEXX Laboratories Inc (IDXX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for IDEXX Laboratories Inc (IDXX), detailing its volatility, financial risk, and investment risk. The company has a current risk assessment score of 7.69, ranking 31st in the Healthcare Equipment & Supplies industry, and a beta value of 1.56, …

IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals

IDEXX Laboratories, Inc. has released its 2025 Corporate Responsibility Report, detailing significant progress in innovation, employee support, and environmental stewardship. The report highlights advancements in veterinary diagnostics, substantial investments in workforce development, and reductions in the company's environmental footprint through renewable energy and fleet …

Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings

IDEXX Laboratories (IDXX) is set to announce its Q2 2026 earnings on August 4th, with analysts anticipating revenue growth of 8.3% and EPS growth of 8.8%. The company has consistently beaten earnings estimates in the past four quarters. Key drivers for Q2 performance are …

IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention

Jensen Investment Management's Q2 2026 investor letter highlighted IDEXX Laboratories (IDXX) as a newly added position, citing its durable competitive advantages including high customer retention and recurring revenue from veterinary diagnostic tests. Despite recent weak share-price performance due to a rotation towards cyclical technology, …

IDEXX Laboratories stock holds firm on recurring diagnostics demand

IDEXX Laboratories reported strong fiscal 2025 results, with revenue reaching $3.9 billion and an operating margin of 31.0%. The company's profitability and growth are driven by recurring veterinary diagnostics demand, especially a 14% increase in companion animal diagnostic recurring revenue. This consistency in expanding …

IDEXX Laboratories Inc (IDXX) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for IDEXX Laboratories Inc (IDXX), highlighting its current earnings forecast score of 7.75 and an average analyst price target of USD 787.50. It details analyst ratings, peer comparisons, and frequently asked questions regarding revenue, EPS, and overall stock …

IDEXX Laboratories Inc (IDXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of IDEXX Laboratories Inc (IDXX) revenue by business segments and geographical regions. It highlights that CAG Diagnostics recurring revenue is the largest contributor, making up 79.17% of total revenue, with the United States accounting for the majority of …

IDEXX Laboratories Inc (IDXX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of IDEXX Laboratories Inc's (IDXX) dividends and stock splits, although it notes that no dividend data is available. It reports the current stock price, market cap, and P/E ratio for IDEXX, indicating that the company has not distributed dividends …

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Despite a recent 9% drop in share price over three months, IDEXX Laboratories (NASDAQ:IDXX) exhibits strong financials, including a high Return on Equity (ROE) of 55%. The company's strategy of reinvesting all profits, coupled with this high ROE, has led to a 15% net …

IDXX|IDEXX Laboratories Inc|Price:539.590|Chg%:-5.410

IDEXX Laboratories Inc (IDXX) shows strong fundamentals with high growth potential, though its valuation is considered fair within its industry. Institutional ownership is high, and analysts currently rate the stock as "Buy" with a target price reflecting significant upside. The stock is currently trading …

IDEXX stock trades near record territory as recurring diagnostics revenue supports double digit grow

IDEXX Laboratories Inc. (IDXX) continues to show strong double-digit growth, driven by recurring diagnostics revenue and high test volumes, according to its Q1 2026 report. The company's Companion Animal Group (CAG) remains its core engine, with operating leverage supporting increased profitability as its installed …

IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides current stock information for Idexx Laboratories Inc (IDXX), including its latest stock price, market capitalization, P/E ratio, and upcoming earnings date. It also lists recent news articles related to medical devices and general market trends, alongside popular community discussions about other …

IDEXX (IDXX) Stock Looks Undervalued On Cash Flow While Earnings Look Overvalued

IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors

IDEXX Laboratories Inc. (IDXX) stock fell 1.35% on Wednesday, closing at $545.00, marking its fourth consecutive day of losses. This underperformance occurred on a generally poor trading day where the S&P 500 Index and Dow Jones Industrial Average also saw declines.

IDEXX Laboratories stock trades near record range as recurring veterinary revenue supports margins

IDEXX Laboratories' stock is performing strongly due to expanding recurring revenue from veterinary diagnostics and software. The company reported double-digit growth in its most recent quarter, driven by companion animal diagnostics and practice management solutions, leading to robust profitability and margin expansion. This solid …